Open Access

REVIEW

Therapeutic options for a rising PSA after radical prostatectomy

Bradley C. Carthon^1,2, David M. Marcus^2,3, Lindsey A. Herrel⁴, Ashesh B. Jani^2,3,4, Peter J. Rossi^2,3,4, Daniel J. Canter^2,4

1 Department of Hematology/Oncology, Emory University, Atlanta, Georgia, USA
2 Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
3 Department of Radiation Oncology, Emory University, Atlanta, Georgia, USA
4 Department of Urology, Emory University, Atlanta, Georgia, USA
Address correspondence to Dr. Daniel J. Canter, Department of Urology, Emory University School of Medicine, 1365 Clifton Rd. NE, Building B, Suite 1400 Atlanta, Georgia 30322 USA

Canadian Journal of Urology 2013, 20(3), 6748-6755.

Abstract

Introduction: Radical prostatectomy is an effective primary treatment for clinically localized prostate cancer. While many patients are cured of their disease after surgery, there are still a significant proportion of men who will develop a biochemical recurrence (BCR). In this review, we detail existing treatment algorithms for this group of patients as well as future therapies that show great promise.
Materials and methods: A review of the literature was performed, and relevant, high-impact articles were identified and reviewed focusing on the treatment of men with BCR after surgery for prostate cancer. Wherever possible, we used data from randomized, controlled trials. When lacking, multi-institutional retrospective studies were utilized.
Results: In a man with BCR, it is important to differentiate between local and distant failure to help guide treatment decision-making. In many of these men, adjuvant or salvage radiotherapy can improve local control, and in the case of salvage radiotherapy, it can improve overall survival (OS). Moreover, there are several systemic therapies available to men with gross metastases and/or castration resistant prostate cancer (CRPC) that have demonstrated a significant survival advantage as well as symptom control.
Conclusions: In the setting of BCR, many treatment options exist. Each modality has an effective role in the management of men with locally recurrent or metastatic prostate cancer. Furthermore, there are currently a number of effective therapies for men who progress to metastatic CRPC. In this review, we present current data detailing the role/efficacy of each therapy for a rising prostate-specific antigen (PSA) after definitive surgical therapy.

---

Keywords

---